ion904
Nucleic acidexperimental
Clinical trial activity
3 trials · 2 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
2
Phase 3
0
Phase 4
0
Earliest trial started Feb 26, 2021 (NCT04731623)
Timeline
Indications
Mechanism of action
- AngiotensinogenANTISENSE INHIBITOR
AGT antisense inhibitor
Chemistry & pharmacology
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL5095350 ↗
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT06864104 | Phase 2 | Apr 10, 2025 | Kardigan, Inc. |
| NCT05314439 | Phase 2 | Apr 26, 2022 | Ionis Pharmaceuticals, Inc. |
| NCT04731623 | Phase 1 | Feb 26, 2021 | Ionis Pharmaceuticals, Inc. |
Showing 3 of 3 trials
Page 1 / 1
Organizations
Research & Development (2)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Ionis Pharmaceuticals, Inc. | For profit | 2 | 2 | 2 | 2021 |
| Kardigan, Inc. | For profit | 1 | 1 | 1 | 2025 |
2 organizations
Page 1 / 1